{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:57:50Z","timestamp":1773712670357,"version":"3.50.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.rpsm.2014.10.006","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T11:14:29Z","timestamp":1425381269000},"page":"97-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efectos de los inductores antiepil\u00e9pticos en la neuropsicofarmacolog\u00eda: una cuesti\u00f3n ignorada. Parte I: Resumen para los cl\u00ednicos de la situaci\u00f3n actual"],"prefix":"10.1016","volume":"8","author":[{"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2014.10.006_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/JCP.0000000000000093","article-title":"False negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: Focus on epilepsy [editorial]","volume":"34","author":"de Leon","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/JCP.0000000000000115","article-title":"False negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part II: Focus on bipolar disorder [editorial]","volume":"34","author":"de Leon","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ps.55.2.125","article-title":"Psychopharmacology. Atypical antipsychotic dosing: The effect of co-medication with anticonvulsants","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.psy.46.3.262","article-title":"The dosing of atypical antipsychotics","volume":"46","author":"de Leon","year":"2005","journal-title":"Psychosomatics."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: A comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1517\/17425255.2012.660918","article-title":"Interactions between antiepileptics and second-generation antipsychotics","volume":"8","author":"de Leon","year":"2012","journal-title":"Exp Opin Drug Metab Toxicol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0035","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Exp Opin Drug Metab Toxicol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0040","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","article-title":"Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants","volume":"10","author":"Italiano","year":"2014","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: A comprehensive review of the literature with proposals to improve future studies","volume":"35","author":"de Leon","year":"2013","journal-title":"Ther Drug Monitor."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.v58n1010b","article-title":"Risperidone and the cytochrome P450 3A","volume":"58","author":"de Leon","year":"1997","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v60n0709","article-title":"A pilot study on risperidone metabolism: The role of cytochrome P450 2D6 and 3A","volume":"60","author":"Bork","year":"1999","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1399-5618.2007.00392.x","article-title":"Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal","volume":"9","author":"O\u2019Neill","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"de Leon","year":"2007","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0075","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.pnpbp.2008.04.018","article-title":"Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model","volume":"32","author":"Botts","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0080","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FTD.0b013e3181c0590e","article-title":"Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder","volume":"31","author":"Spina","year":"2009","journal-title":"Ther Drug Monitor."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0085","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.09lr05902yel","article-title":"Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied","volume":"71","author":"de Leon","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0090","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0095","article-title":"Can valproic acid be an inducer of clozapine metabolism?","author":"Diaz","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0100","series-title":"A Practitioner's Guide for Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities","author":"de Leon","year":"2012"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2008.10.002","article-title":"The future (or lack of future) of personalized prescription in psychiatry","volume":"59","author":"de Leon","year":"2009","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/JCP.0b013e3181a497f1","article-title":"Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing and translation into a message understandable to practicing clinicians","volume":"29","author":"de Leon","year":"2009","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1875692111201010022","article-title":"Role of statistical random-effects linear models in personalized medicine","volume":"10","author":"Diaz","year":"2012","journal-title":"Curr Pharmacogenomics Person Med."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FTD.0b013e318283e3c6","article-title":"The mathematics of drug dose individualization should be built with random effects linear models","volume":"35","author":"Diaz","year":"2013","journal-title":"Ther Drug Monitor."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/clpt.2013.221","article-title":"Pharmacogenomics in psychiatry-from TDM to genomic medicine","volume":"95","author":"Crettol","year":"2014","journal-title":"Clin Pharmacol Therap."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","article-title":"Clinical applications of CYP genotyping in psychiatry","volume":"122","author":"Spina","year":"2015","journal-title":"J Neural Transm"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/JCP.0b013e3182491383","article-title":"Evidence-based medicine versus personalized medicine: Are they enemies? [editorial]","volume":"32","author":"de Leon","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0140","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1124\/dmd.106.013284","article-title":"The time to move cytochrome p450 induction into mainstream pharmacology is long overdue","volume":"35","author":"Smith","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0145","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0150","first-page":"1","article-title":"Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady state","volume":"20","author":"Kerbusch-Herben","year":"2014","journal-title":"Clin Pharmacol Drug Develop."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0155","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0160","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0b013e3182966c2f","article-title":"Interaction between paliperidone and carbamazepine","volume":"35","author":"Yasui-Furukori","year":"2013","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17332","article-title":"A mechanistic approach to antiepileptic drug interactions","volume":"32","author":"Anderson","year":"1998","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0170","series-title":"Treatment of Epilepsy","first-page":"361","article-title":"Drug interactions","author":"Spina","year":"2009"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2174\/138920009789375397","article-title":"The transcriptional regulation of the human CYP2C genes","volume":"10","author":"Chen","year":"2009","journal-title":"Curr Drug Metab."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.clpt.6100431","article-title":"Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2 and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin","volume":"84","author":"Magnusson","year":"2008","journal-title":"Clin Pharm Ther."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0185","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/106002809302700605","article-title":"Unmasking the significant enzyme-inducing effects of phenytoin on serum carbamazepine concentrations during phenytoin withdrawal","volume":"27","author":"Chapron","year":"1993","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0190","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin Ther."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0195","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00007691-199902000-00012","article-title":"Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data","volume":"21","author":"Hirokane","year":"1999","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0200","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.jcp.0000088902.24613.63","article-title":"Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients","volume":"23","author":"Yasui-Furukori","year":"2003","journal-title":"J Clin Psychopharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.rpsm.2014.10.006_bib0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1528-1157.2002.043s2037.x","article-title":"Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs","volume":"43","author":"Spina","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00003088-198409040-00002","article-title":"Pharmacokinetic drug interactions with theophylline","volume":"9","author":"Jonkman","year":"1984","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0215","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-200406000-00005","article-title":"Topiramate serum concentration-to-dose ratio: Influence of age and concomitant antiepileptic drugs and monitoring implications","volume":"26","author":"Ad\u00edn","year":"2004","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0220","unstructured":"Janssen Pharmaceuticals Inc. Topamax (topiramate) tablets for oral use. Topamax (topiramate capsules) sprinkle capsules for oral use (highlights of prescribing information). Titusville, NJ: Janssen Pharmaceuticals Inc., 2012 [consultado 1 Ene 2014]. Disponible en: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=21628112-0c47-11df-95b3-498d55d89593"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0225","unstructured":"Meda Pharmaceuticals Inc. Felbatol (felbamate tablets). Felbatol (felbamate suspension) (prescribing information). Somerset, NJ: Meda Pharmaceuticals Inc.; 2011 [consultado 1 Ene 2014]. Disponible en: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=2f522701-397a-11de-8a39-0800200c9a66"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0920-1211(02)00033-5","article-title":"Time course of lamotrigine de-induction: Impact of step-wise withdrawal of carbamazepine or phenytoin","volume":"49","author":"Anderson","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0235","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0240","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0245","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cpt1978243316","article-title":"Time-course of interaction between carbamazepine and clonazepam in normal man","volume":"24","author":"Lai","year":"1978","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0250","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00004714-200112000-00008","article-title":"Pharmacoepidemiologic investigation of a clonazepam-carbamazepine interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients","volume":"21","author":"Yukawa","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0255","unstructured":"GlaxoSmithKline. Potiga-ezogabine tablet, film coated. Highlights of prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2013 [consultado I Ene 2014]. Disponible en: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=0c60979b-489d-4e7b-8893-468ae00c44bb"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-1211(91)90013-6","article-title":"No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin","volume":"10","author":"Andersen","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","article-title":"Clinically significant drug interactions with newer antidepressants","volume":"26","author":"Spina","year":"2012","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0270","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0447.1989.tb07184.x","article-title":"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine","volume":"350","author":"Greb","year":"1989","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0275","unstructured":"Novartis Pharmaceutical Corporation. TRILEPTAL-oxcarbazepine tablet, film coated. TRILEPTAL- oxcarbazepine suspension. Highlights of prescribing information. East Hannover, NJ: Novartis Pharmaceutical Coporation; 2011 [consultado 1 Ene 2014]. Disponible en: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003088-199018010-00003","article-title":"Pharmacokinetic drug interactions with phenytoin (Part I)","volume":"18","author":"Nation","year":"1990","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0285","unstructured":"Watson Laboratories Inc. Clonazepam, clonazepam tablets. Corona, CA: Watson Laboratories Inc.; 2008 [consultado 1 Ene 2014]. Disponible en: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=acbce0e8-5098-4785-943b-8bdb5ff17fab"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0290","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007691-199802000-00011","article-title":"Phenytoin auto-induction","volume":"20","author":"Chetty","year":"1998","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0295","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/138920008786049311","article-title":"Anticonvulsants-antidepressants pharmacokinetic drug interactions: The role of the CYP450 system in psychopharmacology","volume":"9","author":"Mula","year":"2008","journal-title":"Curr Drug Metab."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0300","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","article-title":"General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs","volume":"46","author":"Ohno","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0305","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1017\/S1461145703003249","article-title":"Glucuronidation enzymes, genes and psychiatry","volume":"6","author":"de Leon","year":"2003","journal-title":"Int J Neuropsychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0310","unstructured":"Lundbeck Inc. ONFI (clobazam). Highlights of prescribing information. Deerfield, IL: Lundbeck Inc, 2011. [consultado 1 Ene 2014]. Disponible en: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setidde03bd69-2dca-459c-93b4-541fd3e9571c"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0315","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0320","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003088-200847100-00004","article-title":"General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information","volume":"47","author":"Ohno","year":"2008","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1212\/WNL.0b013e31823efcf8","volume":"78","author":"Birbeck","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0330","first-page":"287","article-title":"Time-dependence of clobazam and N-desmethylclobazam kinetics in healthy volunteers","volume":"24","author":"Bun","year":"1986","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0335","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-007-0308-2","article-title":"Lamotrigine in children and adolescents: The impact of age on its serum concentrations and on the extent of drug interactions","volume":"63","author":"Reimers","year":"2007","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0340","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00115-009-2906-y","article-title":"Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy","volume":"81","author":"Bauer","year":"2010","journal-title":"Nervenarzt."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.10.005","article-title":"Eslicarbazepine acetate: An update on efficacy and safety in epilepsy","volume":"108","author":"Verrotti","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0350","unstructured":"European Medicines Agency. Zebinix: EPAR Summary for the public (last updated 14\/09\/12). [consultado 1 Ene 2014]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000988\/WC500047225.pdf"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0355","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eplepsyres.2013.04.009","article-title":"Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects","volume":"106","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0360","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eplepsyres.2013.02.020","article-title":"Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol\/levonorgestrel oral contraceptive in healthy women","volume":"105","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0365","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy","volume":"2","author":"Biton","year":"2006","journal-title":"Exp Opin Drug Metab Toxicol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0370","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2125.2011.03941.x","article-title":"Possible drug-drug interaction between quetiapine and lamotrigine\u2014evidence from a Swedish TDM database","volume":"72","author":"Andersson","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0380","first-page":"512","article-title":"Glucuronidation of olanzapine by cDNA-expressed human UGT-glucuronosyltransferases and human liver microsomes","volume":"24","author":"Linnet","year":"2002","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0385","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.1994.tb05938.x","article-title":"Clinical pharmacology and pharmacokinetics of oxcarbazepine","volume":"35","author":"Lloyd","year":"1994","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0390","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00280057","article-title":"Dose dependent enzyme induction by oxcarbazepine","volume":"39","author":"Patsalos","year":"1990","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0400","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4","volume":"48","author":"Andreasen","year":"2007","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0405","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1528-1167.2005.71104.x","article-title":"Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine","volume":"46","author":"Muscatello","year":"2005","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0410","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.jcp.0000085420.74359.29","article-title":"The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms","volume":"23","author":"Baird","year":"2003","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0415","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/sj.npp.1300831","article-title":"Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine","volume":"30","author":"Theis","year":"2005","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0420","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: Results of a retrospective study","volume":"21","author":"May","year":"1999","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0430","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: Influence of dose, age, and comedication","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0435","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0b013e31820fa9ad","article-title":"Serum concentrations of rufinamide in children and adults with epilepsy: The influence of dose, age, and comedication","volume":"33","author":"May","year":"2011","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0440","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0445","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.0013-9580.2003.06203.x","article-title":"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate","volume":"44","author":"Nallani","year":"2003","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0450","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1528-1157.1997.tb01123.x","article-title":"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0455","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","article-title":"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0460","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1528-1157.1997.tb01124.x","article-title":"Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0465","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug-drug interaction and patients\u2019 characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vuci\u0107evi\u0107","year":"2009","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0470","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1528-1157.2003.64402.x","article-title":"Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0475","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00007691-199908000-00094","article-title":"Topiramate decreases lamotrigine concentrations","volume":"21","author":"Wnuk","year":"1999","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0480","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","article-title":"Drug interactions between lamotrigine and psychoactive drugs: Evidence from a therapeutic drug monitoring service","volume":"25","author":"Reimers","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0485","unstructured":"Lundbeck, Inc. Sabril (vigabatrin) tablets film coated. Highlights of prescribing information. Deerfield, IL: Lundbeck, Inc; 2013. [consultado 1 Ene 2014]. Disponible en: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=a5d389d2-d0e1-4395-a2a2-b552808e7f98"},{"key":"10.1016\/j.rpsm.2014.10.006_bib0490","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0090-9556(25)07404-5","article-title":"Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C] vigabatrin in healthy male volunteers","volume":"21","author":"Durham","year":"1993","journal-title":"Drug Met Dispos."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0495","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1111\/j.1365-2125.1989.tb03458.x","article-title":"Interaction between vigabatrin and phenytoin","volume":"27","author":"Rimmer","year":"1989","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0500","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1528-1157.1991.tb05627.x","article-title":"Alterations in the renal excretion of valproate and its metabolites after chronic treatment","volume":"32","author":"Fisher","year":"1991","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0505","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1528-1157.1996.tb00518.x","article-title":"Effect of felbamate on valproic acid disposition in healthy volunteers: Inhibition of beta-oxidation","volume":"37","author":"Hooper","year":"1996","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0510","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","article-title":"Bidirectional interaction of valproate and lamotrigine in healthy subjects","volume":"60","author":"Anderson","year":"1996","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0515","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2125.2000.00191.x","article-title":"Apparent autoinduction of valproate beta-oxidation in humans","volume":"49","author":"McLaughlin","year":"2000","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0520","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0525","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.4161\/cbt.6.9.4567","article-title":"Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity","volume":"6","author":"De Jong","year":"2007","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0530","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0091270004269870","article-title":"Pharmacokinetics of aripiprazole and concomitant lithium and valproate","volume":"45","author":"Citrome","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0535","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.jcp.0000227353.46450.52","article-title":"Valproate lowers plasma concentration of olanzapine","volume":"26","author":"Bergemann","year":"2006","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0540","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0b013e3182693d2a","article-title":"Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking","volume":"34","author":"Haslemo","year":"2012","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0545","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0006-3223(94)90647-5","article-title":"Potential impact of valproic acid therapy on clozapine disposition","volume":"36","author":"Finley","year":"1994","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0550","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1176\/ajp.152.4.650a","article-title":"Valproic acid effects on serum concentrations of clozapine and norclozapine","volume":"152","author":"Longo","year":"1995","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0555","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.toxlet.2010.11.008","article-title":"Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: A possible cause of valproic acid-induced osteomalacia","volume":"200","author":"Vrzal","year":"2011","journal-title":"Toxicol Lett."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0560","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: Cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0565","first-page":"285","article-title":"Clinical consequences of microsomal enzyme-induction by antiepileptic drugs","volume":"2","author":"Perucca","year":"1978","journal-title":"Pharmacol Ther C."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0570","article-title":"Treatment of hypopituitarism in patients receiving antiepileptic drugs","author":"Paragliola","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0575","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00023210-200519030-00003","article-title":"Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy","volume":"19","author":"Isoj\u00e4rvi","year":"2005","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0580","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1172\/JCI27793","article-title":"Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia","volume":"116","author":"Zhou","year":"2006","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0585","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2014.919255","article-title":"The problem of osteoporosis in epileptic patients taking antiepileptic drugs","volume":"13","author":"Miziak","year":"2014","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0590","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00228-005-0056-0","article-title":"Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: Involvement of glucuronosyltransferase induction","volume":"61","author":"Benedetti","year":"2005","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0595","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0074-7742(08)00019-6","article-title":"Metabolic effects of AEDs: Impact on body weight, lipids and glucose metabolism","volume":"83","author":"Sheth","year":"2008","journal-title":"Int Rev Neurobiol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0600","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1734-1140(09)70082-9","article-title":"Atherosclerotic risk among children taking antiepileptic drugs","volume":"61","author":"Jakubus","year":"2009","journal-title":"Pharmacol Rep."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2012.07.003","article-title":"Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy","volume":"102","author":"Belcastro","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0610","first-page":"e51","article-title":"Mechanism of drug-induced gingival overgrowth revisited: A unifying hypothesis","volume":"21","author":"Brown","year":"2014","journal-title":"Oral Dis."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0615","first-page":"9","article-title":"Influence of spirulina on the phenytoin induced haematological changes","volume":"26","author":"Thaakur","year":"2007","journal-title":"Anc Sci Life."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0620","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138920009788498978","article-title":"Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction","volume":"10","author":"Almond","year":"2009","journal-title":"Curr Drug Metab."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0625","unstructured":"American Pharmacist Association. Drug information handbook, 21st edition. Hudson, OH: Lexi-Comp, Inc.; 2012."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0630","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4088\/JCP.v65n0520e","article-title":"Dosing differences between valproic acid concentrate and divalproex sodium: A case report","volume":"65","author":"Coffey","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0635","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0278-5846(03)00148-9","article-title":"Serious respiratory infections can increase clozapine levels and contribute to side effects: A case report","volume":"27","author":"de Leon","year":"2003","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0640","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0645","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003088-199325020-00003","article-title":"Clinical pharmacokinetics of drugs in obesity","volume":"25","author":"Cheymol","year":"1993","journal-title":"An update. Clin Pharmacokinet."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0650","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","article-title":"Assessment of CYP1A2 activity in clinical practice: why, how, and when?","volume":"97","author":"Faber","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0655","doi-asserted-by":"crossref","first-page":"e62489","DOI":"10.1371\/journal.pone.0062489","article-title":"Genetic variants of pregnane X receptor (PXR) and CYP2B6 affect the induction of bupropion hydroxylation by sodium ferulate","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0660","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00228-008-0594-3","article-title":"Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation","volume":"65","author":"Fan","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0665","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bcp.12207","article-title":"Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19","volume":"77","author":"Ke","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0670","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/QAI.0b013e318183a425","article-title":"Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects","volume":"49","author":"Robertson","year":"2008","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0675","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1128\/AAC.01600-07","article-title":"Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir","volume":"52","author":"Kharasch","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0680","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.psy.45.3.262","article-title":"Antiretrovirals, part 1: overview, history, and focus on protease inhibitors","volume":"45","author":"Wynn","year":"2004","journal-title":"Psychosomatics."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0685","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1176\/appi.psy.45.6.524","article-title":"Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs. NNRTIs, and fusion inhibitors)","volume":"45","author":"Zapor","year":"2004","journal-title":"Psychosomatics."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0690","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/dmd.32.3.348","article-title":"Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers","volume":"32","author":"Faucette","year":"2004","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0695","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1213\/ANE.0b013e3182918252","article-title":"Mechanism of autoinduction of methadone N-demethylation in human hepatocytes","volume":"117","author":"Campbell","year":"2013","journal-title":"Anesth Analg."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0700","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/dmd.112.046276","article-title":"Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone","volume":"41","author":"Choi","year":"2013","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0705","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1124\/mol.110.065540","article-title":"Regulation of CYP2C19 expression by estrogen receptor \u03b1: implications for estrogen-dependent inhibition of drug metabolism","volume":"78","author":"Mwinyi","year":"2010","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.rpsm.2014.10.006_bib0710","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1074\/jbc.M113.526798","article-title":"Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice","volume":"289","author":"Koh","year":"2014","journal-title":"J Biol Chem."}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989114001487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989114001487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:29:31Z","timestamp":1761823771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989114001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":141,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1888989114001487"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2014.10.006","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectos de los inductores antiepil\u00e9pticos en la neuropsicofarmacolog\u00eda: una cuesti\u00f3n ignorada. Parte I: Resumen para los cl\u00ednicos de la situaci\u00f3n actual","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}